On Oct 29, 2025, GSK reported earnings of 0.55 USD per share (EPS) for Q3 25, beating the estimate of 0.48 USD, resulting in a 12.80% surprise. Revenue reached 8.55 billion, compared to an expected 8.57 billion, with a -0.28% difference. The market reacted with a +5.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 8.70 billion USD, implying an decrease of -58.18% EPS, and increase of 1.78% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
Dec 22, 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Surprise
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, GSK plc - ADR reported EPS of $0.55, beating estimates by 12.8%, and revenue of $8.55B, -0.28% below expectations.
How did the market react to GSK plc - ADR's Q3 2025 earnings?
The stock price moved up 5.1%, changed from $43.70 before the earnings release to $45.93 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Feb 04, 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 9
analysts, GSK plc - ADR is expected to report EPS of $0.23 and revenue of $8.70B for Q4 2025.